GXCPC1 is an allogeneic adipose-derived stem cells (ADSCs) therapy in treating patients with osteoarthritis (OA). GXCPC1 has demonstrated that it possesses great therapeutic potential in regenerating cartilage according to GXCPC1's pre-clinical research. Currently, GXCPC1 has completed its clinical trial phase I/II, and the clinical trials' results have been published. In the human trial, GXCPC1 shows the improvement of net change in pain, knee function, and well-tolerance after transplantation. Moreover, subjects receiving high-dose GXCPC1 (4 X 10^7 GXCPC1) show better outcomes in comparison to the low dose group (6.7 x 10^6 GXCPC1) generally. (NCT03943576). Overall, the clinical trial has shown that the intra-articular injection of ADSCs was safe and well-tolerated in subjects with therapeutic alternatives to treat knee OA.


SCI Journal


The Knee

Dec. 2018

The effect of adipose-derived mesenchymal stem cells and chondrocytes with platelet-rich fibrin releasates augmentation by intra-articular injection on acute osteochondral defects in arabbit model.

Cell Teansplantation

Dec. 2023

Safety and tolerability of intra-articular injection of adipose-derived mesenchymal stem cells GXCPC1 in 11 Subjects with knee osteoarthritis: A nonrandomized pilot study without a control arm.